GenFleet and BeiGene partner for Phase Ib/II lymphoma treatment trial
GenFleet Therapeutics has signed a clinical trial collaboration and supply agreement with BeiGene Switzerland to commence a Phase Ib/II clinical …
Aurion doses first subject in Phase I/II corneal oedema trial in Canada
Aurion Biotech has dosed the first Canadian subject in the Phase I/II ABA-1, CLARA clinical trial of AURN001, a new …
InnoCare doses first subject in Phase Ib NSCLC combination treatment trial
InnoCare Pharma has dosed the first subject in a Phase Ib clinical trial assessing a combination its ICP-189 plus ArriVent …
Bristol Myers Squibb’s Phase III trial of KRAZATI meets endpoints
Bristol Myers Squibb (BMS) has announced that its Phase III KRYSTAL-12 clinical trial of KRAZATI (adagrasib) for treating non-small cell …
Novocure’s TTFields device slows metastasis in NSCLC
Novocure’s Tumor Treating Fields (TTFields) therapy met its primary endpoint in the Phase III METIS trial by slowing the progression …
Nexalin’s device improves symptoms of mild traumatic brain injury
Nexalin Technology has revealed positive data from a clinical trial that evaluated its neurostimulation device in veteran patients with combat-related …
Photopharmics kickstarts phototherapy trial for Parkinson’s disease
US-based equipment manufacturer Photopharmics has announced the initiation of its ‘Celeste light for PD’ clinical trial investigating the Celeste phototherapy …
Seyltx buys Algernon’s Phase II chronic cough therapy
US-based Seyltx has closed an agreement to acquire Algernon Pharmaceuticals’ chronic cough therapy, ifenprodil (NP-120). Algernon received a purchase price …
Iambic begins dosing in trial of IAM1363 for HER2-driven cancer
Iambic Therapeutics has initiated the dosing of the first subject in its Phase I/Ib clinical trial of IAM1363, a novel …
Immuneering doses first subject in Phase I/IIa solid tumour trial
Immuneering has dosed the first subject in its Phase I/IIa clinical trial of IMM-6-415 for the treatment of advanced solid …
Virion reports safety data from Phase IB HBV immunotherapy trial
Virion Therapeutics has reported encouraging safety outcomes from the first-in-human Phase IB clinical study of VRON-0200, a checkpoint modifier immunotherapy …
Beckley Psytech reports initial positive data from TRD treatment trial
Beckley Psytech has released initial positive findings from its Phase IIa clinical study of BPL-003 for treating treatment-resistant depression (TRD). The …
89bio wins EMA priority status for MASH candidate pegozafermin
The European Medicine’s Agency (EMA) has granted priority medicines (PRIME) status to 89bio’s pegozafermin, a drug being evaluated to treat …
Pfizer’s Velsipity UK approval raises competition in the ulcerative colitis market
The recent approval of Pfizer’s oral drug, Velsipity (etrasimod), by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for …
Cleerly touts new data for AI cardiovascular software
Digital healthcare company Cleerly has announced that positive data from two studies investigating its AI-QCT ISCHEMIA software device has been …